European expansion

As a strategic limited partner in Gilde Healthcare's new fund, Johnson & Johnson (NYSE:JNJ) is expanding its European network with a second VC partner whose focus complements the first. Gilde Healthcare's new €250 million ($281.1 million) fund has a remit to invest in later-stage therapeutics as well as in medtech and digital health companies.

J&J already has a window into early stage single-asset therapeutics companies in Europe through its investment in Medicxi Ventures' Medicxi Ventures 1 fund that closed at €210 million ($250 million) in February...